About Semax Chemical

What this site is

Semax Chemical is a newsroom for the Semax literature: it works the peer-reviewed record like a beat, files each finding in plain English, and cites every figure to its source. No clinic stands behind the masthead and no clinician on the desk; the paper diagnoses no one, advises no one, and sells nothing — there is no order to place. Its business is reading the published science and showing where each line came from.

The brief is narrow on purpose: read the Semax literature carefully, report what the studies actually measured, write it in plain English, and cite every figure to its source. The neuroprotection-in-ischemia record gets the closest reading, because that is where the evidence is deepest — and the gaps get the same plain treatment as the findings.

The word 'chemical' in the name

The 'chemical' in Semax Chemical is editorial framing — a description of how the compound is actually classified outside Russia and Ukraine, where Semax is an unscheduled research chemical rather than an approved medicine. It is not a claim that this site sells, supplies, or formulates anything. We hold no inventory, take no orders, and quote no prices. The name signals the regulatory reality of the molecule, nothing more.

How we handle the evidence

Three rules govern the writing. First, every quantitative claim — a dose, a binding constant, an enzyme IC50, an infarct-volume change — is tied to a numbered study in the references. Second, animal data are described as animal data, with the species and route stated, and no figure is reframed as a human dose. Third, community reports are labeled as anecdote, kept separate from the cited findings, and never dressed up as proof. Where the record is honest about its own limits — the Russian concentration of the literature, the missing Western trials, the minutes-long half-life — so are we.